Deal Ticker: Kellerhals Carrard is pleased to have advised Positrigo on its recent financing round.

Early diagnosis of Alzheimer’s disease can change lives. 

Detecting neurodegenerative diseases at their earliest stages opens the door to timely interventions, more effective treatments, and improved patient outcomes – yet many people lack access to these critical diagnostic tools. Positrigo is on a mission to change that.

Positrigo AG, a medtech spin-off from ETH Zurich, has successfully raised another CHF 7 million of financing in a round led by HealthCap, a renowned European investor in biosciences, and with participation from NAVIVO CAPITAL as well as several family offices and individuals that continuously support the growth of the company.

As a leading developer of state-of-the-art, ultra-compact, and cost-effective brain PET imaging solutions, Positrigo is revolutionizing healthcare access. Its flagship neuroimaging device aims to significantly broaden access to the early diagnosis of Alzheimer’s disease and other neurological disorders, addressing a major unmet need in healthcare systems worldwide.

The funds raised in this round will enable Positrigo to accelerate clinical development, fast-track regulatory approval, and prepare for market entry in the US and European key regions. By leveraging these advancements, Positrigo is one step closer to making life-changing diagnostic tools accessible to millions around the world.

We are grateful for Positrigo’s continued trust put in us and have advised Positrigo on all legal aspects of this financing round. The Kellerhals Carrard team was led by Dario Silberschmidt (Partner, Corporate/VC) and included Kathrin Moser (Senior Associate, Corporate/VC), Elga Tozzi (Of Counsel, Tax) and Melissa Wiss (Paralegal, Corporate/VC).

Congratulations to Jannis Fischer, Max Ahnen and all other founders and members of the management and board of Positrigo on reaching this significant milestone! We look forward to continuing to support your journey as you bring cutting-edge medical innovation to the world.